Companies › HC Biopharma
4 active drug programs in 9 registered trials: 8 Phase 1, 1 Phase 2; Oncology, Other, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| HC010 PD-L1 inhibitor | – | Phase 2 | NSCLC; Advanced Solid Tumor; Advanced Solid Tumor Cancer | Dec 2026 |
| HC006 | – | Phase 1 | Advanced Solid Tumor; Advanced Cancer; Advanced Solid Tumor Cancer | May 2027 |
| HC034S EGFR inhibitor monoclonal antibody (cetuximab biosimilar) | EGFR | Phase 1 | Cetuximab | Jun 2027 |
| HC022 | – | Phase 1 | Systemic Lupus Erythematosus | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06657703 | HC022 | Phase 1 | Systemic Lupus Erythematosus | Immunology | Aug 2025 |
| NCT06307925 | HC010 | Phase 1 | Advanced Solid Tumor | Oncology | Dec 2025 |
| NCT06304571 | HC006 | Phase 1 | Advanced Solid Tumor | Oncology | Mar 2026 |
| NCT07169552 | HC010 | Phase 2 | NSCLC | Oncology | Dec 2026 |
| NCT07381829 | HC010 | Phase 1 | Advanced Solid Tumor Cancer | Oncology | Dec 2026 |
| NCT06963814 | HC006 | Phase 1 | Advanced Cancer | Oncology | May 2027 |
| NCT07813468 | HC034S | Phase 1 | Cetuximab | Other | Jun 2027 |
| NCT07477743 | HC010 | Phase 1 | Advanced Solid Tumor Cancer | Oncology | Dec 2027 |
| NCT07477743 | HC006 | Phase 1 | Advanced Solid Tumor Cancer | Oncology | Dec 2027 |
AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group
Nanjing Sanhome Pharmaceutical Jiangsu Aosaikang Pharmaceutical Jiangsu Alphamab Biopharmaceuticals ArriVent BioPharma Wayshine Biopharm
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.